ArticleJournal of global health2025
COVID-19 vaccination and miscarriage risk: RNA-seq and bioinformatics analysis at the maternal-foetal interface.
Article in Journal of global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vaccine hesitancy persists because definitive evidence regarding the underexplored safety of COVID-19 vaccines in pregnancy is still lacking, particularly concerning their effects on the maternal-foetal interface (MFI) and potential links to miscarriage. We aimed to verify whether COVID-19 vaccines modulate gene expression at the MFI, thereby influencing recurrent miscarriage. Methods: We conducted an RNA sequencing analysis on decidual tissues from six pairs of early pregnancy participants, both vaccinated and unvaccinated. We extracted the data sets associated with COVID-19 placenta (GSE181238) and recurrent miscarriage (GSE22490) from the Gene Expression Omnibus database for further bioinformatic analysis, focussing on the expression, function, and distribution of core genes at the MFI. Results: Compared to the control group, 879 differentially expressed genes (P < 0.05; fold changes >1.5; false discovery rate <0.05) were identified in the vaccinated group. Complement activation and cell adhesion pathways were up-regulated, while the graft-vs-host response was down-regulated. The vaccine down-regulated some genes overexpressed in recurrent miscarriage cases. Three significant genes - FOS, FOSB, and LY96 - associated with miscarriage were identified; these genes are up-regulated during infection but suppressed by the vaccine. Functional enrichment analysis revealed the vaccine's immune activity, similar to but weaker than COVID-19 infection, and it inhibited certain miscarriage-related pathways, such as the tumour necrosis factor signalling pathway. Gene set variation analysis suggested a positive influence of the vaccine on immune tolerance at MFI. Conclusions: This study indicates that the COVID-19 vaccine may exert nonnegative effects on the maternal-foetal immune micro-environment and is unlikely to increase the risk of miscarriage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.